Design Therapeutics (DSGN) Assets Average (2021 - 2026)

Design Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $228.3 million for Q1 2026.

• In Q1 2026, Assets Average fell 6.72% year-over-year to $228.3 million; the TTM figure through Mar 2026 stood at $228.3 million (down 6.72% YoY), while the FY2025 annual figure was $239.1 million, down 11.71% from the prior year.
• Assets Average came in at $228.3 million for Q1 2026 at Design Therapeutics, up from $219.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $384.7 million in Q1 2022 to a low of $217.3 million in Q3 2025.
• A 5-year average of $290.5 million and a median of $284.2 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 71.59% in 2022 and fell 18.18% in 2025, its largest moves.
• Design Therapeutics' Assets Average stood at $347.9 million in 2022, then decreased by 15.26% to $294.8 million in 2023, then retreated by 12.86% to $256.9 million in 2024, then dropped by 14.75% to $219.0 million in 2025, then grew by 4.26% to $228.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $228.3 million, $219.0 million, and $217.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison